Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) h...
The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France...
Bristol Myers Squibb (NYSE: BMY) has announced the European Commission's (EC) expanded approval of Reblozyl® (luspatercept) for the first-line ...
LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, a...
— If approved, would confirm 2021 conditional approval and expand indication to more patients — HUTCHMED (China) Lim...
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal paras...
GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s revolutionary nCommand Lite technology, aimed at mitig...
Johnson & Johnson has announced the approval of OPSYNVI® by the U.S. Food and Drug Administration (FDA), marking a significant advanc...
Orchard Therapeutics, now under the stewardship of Kyowa Kirin, announces a historic milestone as the U.S. Food and Drug Administration (FDA) grants approv...
Biotechnology Innovation Organization (BIO), a leading lobbying group in Washington, D.C., announced its decision to sever ties with WuXi AppTec, a Chinese...
Recognizing the severity of the cyberattack, HHS has been actively engaged in regular discussions with UHG leadership, state partners, and a wide a...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to d...
Fresenius Kabi announced it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms o...
© 2025 Biopharma Boardroom. All Rights Reserved.
